Evaluate clinical effectiveness of Azvudine with data rather than speculation

Journal of Medical VirologyVolume 95, Issue 7 e28926 LETTER TO THE EDITOR Evaluate clinical effectiveness of Azvudine with data rather than speculation Daishi Li, Daishi Li Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China Furong Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorYihuang Liu, Yihuang Liu Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China Furong Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorMinxue Shen, Corresponding Author Minxue Shen [email protected] Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China Furong Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, China Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, Hunan, China Correspondence Guangtong Deng and Minxue Shen, Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Email: [email protected] and [email protected]Search for more papers by this authorGuangtong Deng, Corresponding Author Guangtong Deng [email protected] orcid.org/0000-0002-4424-9727 Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China Furong Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, China Correspondence Guangtong Deng and Minxue Shen, Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Email: [email protected] and [email protected]Search for more papers by this author Daishi Li, Daishi Li Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China Furong Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorYihuang Liu, Yihuang Liu Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China Furong Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorMinxue Shen, Corresponding Author Minxue Shen [email protected] Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China Furong Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, China Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, Hunan, China Correspondence Guangtong Deng and Minxue Shen, Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Email: [email protected] and [email protected]Search for more papers by this authorGuangtong Deng, Corresponding Author Guangtong Deng [email protected] orcid.org/0000-0002-4424-9727 Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China Furong Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, China Correspondence Guangtong Deng and Minxue Shen, Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Email: [email protected] and [email protected]Search for more papers by this author First published: 05 July 2023 https://doi.org/10.1002/jmv.28926 Daishi Li and Yihuang Liu contributed equally to this study. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Gao Y, Luo Z, Hu Z, et al. Real-world effectiveness of azvudine: elixir or equivocal answer? J Med Virol. 2023; 95(4):e28756. 2Shen M, Xiao C, Sun Y, et al. Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study. medRxiv. 2023;2023.01.23.23284899. 3Deng G, Li D, Sun Y, et al. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study. J Med Virol. 2023; 95(4):e28756. 4Zhang JL, Li YH, Wang LL, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021; 6:414. 5Ren Z, Luo H, Yu Z, et al. A randomized, open-label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv Sci. 2020; 7:2001435. 6Tian F, Chen Z, Feng Q. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2023; 95(4):e28732. 7Liu J, Pan X, Zhang S, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac. 2023; 33:100694. 8Dian Y, Meng Y, Sun Y, et al.Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J Infect. 2023;S0163-4453(23):00290-6. 9 WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022; 399(10339): 1941-1953. 10Bramante CT, Buse JB, Liebovitz DM, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;S1473-3099(23):00299-2. Volume95, Issue7July 2023e28926 ReferencesRelatedInformation